Gilead Sciences stock gains support as HSBC lifts price target to USD 175
Published on 09/11/2026 at 22:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences stock (ISIN US3755581036) ended the trading session on Nasdaq at USD 145.16 on September 10, 2026, up 0.24 percent from the prior close and trading in a range around the mid-USD 140s during the day. According to price data compiled from recent market coverage, this level leaves the shares trading moderately below several major analysts’ longer-term targets as of September 11, 2026.
HSBC lifts Gilead price target to USD 175
A fresh catalyst for Gilead Sciences stock came from HSBC, which increased its price target on the biopharmaceutical group from USD 155 to USD 175 and reaffirmed a Buy rating on September 10, 2026. As TipRanks reported on September 11, 2026, HSBC analyst Morten Herholdt raised the firm’s target to USD 175 from USD 155 to reflect updated pipeline assumptions and a lower perceived sector risk premium. The 12.9 percent increase in the target price underscores confidence that Gilead can grow earnings and cash flow beyond current consensus expectations.
Additional coverage of the move shows the new HSBC objective sitting notably above where Gilead Sciences stock last closed. According to a summary of recent analyst actions on MarketBeat dated September 11, 2026, HSBC’s boost to USD 175 came alongside a maintained Buy recommendation on Gilead, positioning the target roughly USD 29.84 above the latest Nasdaq close of USD 145.16. For investors, that gap quantifies the upside HSBC still sees from current levels.
Analyst consensus and valuation context
Beyond HSBC’s move, Gilead Sciences stock carries broad analyst support. According to MarketBeat on September 11, 2026, Gilead has a consensus rating of Moderate Buy based on one Strong Buy, 23 Buy and five Hold recommendations, with no Sell ratings. The same overview cites a consensus price target of USD 158.78, only moderately above the recent market price, suggesting analysts overall expect steady rather than explosive appreciation from today’s valuation.
The distance between the consensus target and the last close is an important reference point. With Gilead Sciences stock at USD 145.16 as of September 10, 2026 and the consensus target at USD 158.78, the implied upside from the broader analyst community is around 9.4 percent. HSBC’s USD 175 target, by contrast, sits approximately 20.6 percent above the closing price, highlighting that its stance is more optimistic than the average. The spread between HSBC and the consensus thus frames a range of expectations about how much Gilead’s pipeline and earnings can re-rate the shares over the coming quarters.
MarketBeat also characterizes analyst interest in the name as solid, noting that Gilead Sciences has been the subject of ten research reports in the past 90 days as of September 11, 2026. This level of coverage reflects the company’s central role in large-cap biotechnology and the market’s focus on how management executes on HIV, oncology and inflammatory disease franchises while navigating pricing and policy changes.
Recent earnings and guidance frame fundamental picture
On the fundamental side, recent results and guidance provide context for the current analyst debate. A sector-focused report on Gilead’s latest full-year guidance, published on September 11, 2026 by Hong Kong outlet etnet, summarizes that in the most recently reported fourth quarter Gilead increased revenue by 5 percent year on year to USD 7.9 billion, beating analyst expectations of USD 7.7 billion for the quarter. The same piece notes that adjusted earnings per share reached USD 1.86, ahead of the market’s forecast of USD 1.81, and highlights that HIV product sales grew 6 percent to USD 5.8 billion over the period.
For investors, those fourth-quarter figures serve as a historical benchmark rather than the current year’s snapshot, but they show that Gilead has been able to deliver modest top-line growth while slightly beating consensus on profitability. The more recent pressure point lies in the updated outlook. As etnet reports, Gilead’s guidance for the 2026 fiscal year calls for product sales between USD 29.6 billion and USD 30.0 billion, compared with analyst expectations around USD 30.2 billion. On adjusted earnings, management now anticipates a non-GAAP earnings per share range of USD 8.45 to USD 8.85 for 2026, a touch below the consensus near USD 8.76 at the time of the update.
The gap between Gilead’s own sales guidance and market estimates is small in absolute terms but important in signaling management’s caution. A midpoint product sales projection of roughly USD 29.8 billion sits about USD 0.4 billion under the rough USD 30.2 billion analyst consensus cited in the etnet coverage, while the midpoint EPS guidance of around USD 8.65 is only slightly below the USD 8.76 figure. This indicates that the company is guiding conservatively, factoring in headwinds such as evolving drug pricing agreements and potential subsidy changes, rather than promising aggressive growth.
Earnings expectations for late 2026
Analyst models for the coming quarters complement the company’s guidance. Consensus data on Yahoo Finance as of September 10, 2026 show that for the current quarter ending September 2026, analysts on average expect Gilead to generate USD 7.76 billion in revenue and USD 2.14 in earnings per share. For the following quarter ending December 2026, the same consensus stands at USD 8.13 billion in revenue and USD 2.19 in EPS, indicating an anticipated sequential revenue increase of about 4.8 percent and a modest earnings uplift if forecasts are met.
The dispersion around these estimates illustrates both upside and downside risks. Yahoo Finance’s breakdown notes that for the September 2026 quarter, revenue projections range from USD 7.52 billion to USD 7.96 billion, and EPS estimates span from USD 1.90 to USD 2.68. The revenue range of roughly USD 0.44 billion and EPS range of USD 0.78 suggest that analysts differ meaningfully in how they weigh factors such as HIV franchise momentum, oncology portfolio uptake and the pace of decline in COVID-related therapeutics.
Looking further out, the same consensus table cited by Yahoo Finance indicates that analysts expect current-year 2026 revenue around USD 30.69 billion and next-year 2027 revenue near USD 32.68 billion. That would represent top-line growth of roughly 6.5 percent from 2026 to 2027 if forecasts prove accurate. While the current-year consensus revenue is somewhat above the product sales guidance range shared in recent commentary, the difference remains relatively small, showing that the street’s expectations are broadly aligned with management’s guidance corridor.
Risk factors and policy backdrop
The policy environment for drug pricing remains a key variable for Gilead Sciences stock. As etnet’s September 11, 2026 article reports, Gilead’s updated guidance acknowledges headwinds from a new medication pricing agreement with U.S. authorities and uncertainty around certain subsidy policies. These elements contributed to the company’s decision to set its 2026 earnings outlook slightly below prevailing consensus, underscoring that regulatory and reimbursement dynamics can weigh on margin expansion even when core product volumes are growing.
Another risk highlighted in the same coverage is the decline in sales of Gilead’s COVID-19 treatment remdesivir. etnet notes that revenue from this therapy fell 37 percent year on year to USD 212 million in the most recent quarter, reflecting a sustained drop in hospitalization rates tied to COVID infections. While this business now forms a relatively small portion of overall revenue, the sharp decline illustrates how quickly pandemic-related tailwinds can fade, leaving the company more reliant on its HIV and oncology portfolios to drive growth.
For investors, the combination of policy headwinds and shifting product mix means that Gilead’s ability to sustain mid-single-digit revenue growth and deliver on its earnings guidance will depend on continued strength in core franchises and successful pipeline execution. In that context, HSBC’s higher target and maintained Buy rating can be read as a vote of confidence that the company’s innovation and portfolio diversification will offset pricing pressures over time.
Market performance and sector comparison
Recent performance data indicate that Gilead Sciences stock has outpaced the broader market over the year to date. According to the total-return figures displayed on the UK edition of Yahoo Finance as of September 10, 2026, Gilead shows a year-to-date return of 19.43 percent compared with the S&P 500 benchmark. While the exact S&P 500 figure in that table is not repeated in the snippet, the YTD gain for Gilead clearly reflects meaningful absolute performance in 2026.
MarketBeat’s Gilead overview also places the shares within a relatively strong valuation and performance context among large biotech peers. The site lists a 52-week trading band for Gilead Sciences stock between USD 108.46 and USD 157.29, with a recent price point around USD 144.81 as of its September 11, 2026 update. With the last Nasdaq close at USD 145.16 on September 10, 2026, the stock is trading roughly 33.8 percent above its 52-week low and about 7.7 percent below its 52-week high, showing that the current level is closer to the upper end of its yearly range but still below peak valuations.
At the same time, MarketBeat cites a market capitalization of approximately USD 179.56 billion for Gilead as of its latest data update in September 2026. This places the company among the largest biotechnology names globally, and the scale matters for risk assessment: large-cap biopharma stocks like Gilead typically exhibit lower idiosyncratic volatility than smaller, single-asset biotech firms, but they remain exposed to pipeline outcomes and major trial readouts.
Upcoming earnings dates and investor checkpoints
Institutional and retail investors alike will be watching the next formal update from Gilead closely. An overview of upcoming biotech sector reporting dates on MarketBeat references an estimated next earnings date for Gilead Sciences around November 2, 2026. While the snippet suggests that this is an estimated schedule rather than a formally confirmed company announcement, it provides a working timeframe within which investors can expect the next detailed quarterly set of numbers and guidance.
Until then, interim signals will come from analyst updates and sector developments. The recent HSBC target increase is one example of how new information about pipeline prospects and sector valuation can translate quickly into changes in analyst models. Future rating changes or target adjustments from other banks could either narrow or widen the spread between consensus and more bullish calls like HSBC’s, potentially influencing how Gilead Sciences stock trades relative to its biotech peers.
Gilead Sciences stock near upper end of its 52-week range
Against this backdrop, the current price level encapsulates both the progress Gilead has made and the expectations embedded in the shares. Gilead Sciences stock closed at USD 145.16 on Nasdaq on September 10, 2026, with that reference price sitting well above the 52-week low of USD 108.46 but still below the 52-week high of USD 157.29 reported in MarketBeat’s latest data. For investors, the combination of a Moderate Buy consensus, a USD 158.78 average target and HSBC’s more optimistic USD 175 objective suggests that the market already acknowledges Gilead’s strengths but still sees room for measured upside if the company executes on its guidance and pipeline.
Gilead Sciences stock at a glance
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Trading venue: Nasdaq
- Price (as of September 10, 2026, 16:00): 145.16 USD
- Market capitalization: 179.56 billion USD (as of September 11, 2026)
- Sector / Industry: Biotechnology / Biopharmaceuticals
- Index membership: S&P 500
- Next earnings date: November 2, 2026 (estimated per sector overview)
